Home LiteratureArticle Details
PMID: 17919486 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.

Gastroenterology ·Vol. 133 ·No. 4 ·2007-10-00 ·Pages 1099-105; quiz 1340-1

Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T

Abstract

Although inflammation is presumed to contribute to colonic neoplasia in ulcerative colitis (UC), few studies have directly examined this relationship. Our aim was to determine whether severity of microscopic inflammation over time is an independent risk factor for neoplastic progression in UC. A cohort of patients with UC undergoing regular endoscopic surveillance for dysplasia was studied. Degree of inflammation at each biopsy site had been graded as part of routine clinical care using a highly reproducible histologic activity index. Progression to neoplasia was analyzed in proportional hazards models with inflammation summarized in 3 different ways and each included as a time-changing covariate: (1) mean inflammatory score (IS-mean), (2) binary inflammatory score (IS-bin), and (3) maximum inflammatory score (IS-max). Potential confounders were analyzed in univariate testing and, when significant, in a multivariable model. Of 418 patients who met inclusion criteria, 15 progressed to advanced neoplasia (high-grade dysplasia or colorectal cancer), and 65 progressed to any neoplasia (low-grade dysplasia, high-grade dysplasia, or colorectal cancer). Univariate analysis demonstrated significant relationships between histologic inflammation over time and progression to advanced neoplasia (hazard ration (HR), 3.0; 95% CI: 1.4-6.3 for IS-mean; HR, 3.4; 95% CI: 1.1-10.4 for IS-bin; and HR, 2.2; 95% CI: 1.2-4.2 for IS-max). This association was maintained in multivariable proportional hazards analysis. The severity of microscopic inflammation over time is an independent risk factor for developing advanced colorectal neoplasia among patients with long-standing UC.

MeSH Terms
Adult Cohort Studies Colitis, Ulcerative/complications,pathology Colonoscopy Colorectal Neoplasms/etiology,pathology Databases as Topic Disease Progression Female Follow-Up Studies Humans Inflammation/complications,pathology Male Proportional Hazards Models Risk Assessment Risk Factors Severity of Illness Index Time Factors
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Gupta Roopali Bansal
Department of Medicine, The University of Texas Southwestern, Dallas, Texas, USA.
Harpaz Noam
Itzkowitz Steven
Hossain Sabera
Matula Sierra
Kornbluth Asher
Bodian Carol
Ullman Thomas
References (28)
28 references, click to expand
  1. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study.
    Gastroenterology. 2006 Jun;130(7):1941-9 PMID: 16762617
  2. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?
    Lancet. 1994 Jan 8;343(8889):71-4 PMID: 7903776
  3. Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis.
    Am J Gastroenterol. 1998 Jun;93(6):872-80 PMID: 9647011
  4. Patients with low-grade dysplasia should be advised to undergo colectomy.
    Inflamm Bowel Dis. 2003 Jul;9(4):267-9; discussion 273-5 PMID: 12902850
  5. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance.
    Gastrointest Endosc. 2000 Feb;51(2):123-8 PMID: 10650251
  6. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease.
    Inflamm Bowel Dis. 2005 Mar;11(3):314-21 PMID: 15735438
  7. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome.
    Hum Pathol. 1989 Oct;20(10):1008-14 PMID: 2793156
  8. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis.
    Inflamm Bowel Dis. 2003 Nov;9(6):351-5 PMID: 14671483
  9. Is histology useful for the assessment of the efficacy of immunosuppressive agents in IBD and if so, how should it be applied ?
    Acta Gastroenterol Belg. 2004 Jul-Sep;67(3):285-9 PMID: 15587337
  10. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis.
    J Pathol. 2001 Jun;194(2):152-7 PMID: 11400142
  11. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
    Gastroenterology. 2004 Feb;126(2):451-9 PMID: 14762782
  12. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.
    Hum Pathol. 1983 Nov;14(11):931-68 PMID: 6629368
  13. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis.
    Gastroenterology. 1994 Oct;107(4):934-44 PMID: 7926483
  14. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps.
    Gastroenterology. 1999 Dec;117(6):1295-300 PMID: 10579970
  15. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia.
    Gastroenterology. 1992 Aug;103(2):431-8 PMID: 1634062
  16. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation.
    Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17 PMID: 15194558
  17. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis.
    Gastroenterology. 2003 Nov;125(5):1311-9 PMID: 14598247
  18. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.
    Gastroenterology. 1994 Jul;107(1):117-20 PMID: 7912678
  19. Ulcerative colitis and colorectal cancer. A population-based study.
    N Engl J Med. 1990 Nov 1;323(18):1228-33 PMID: 2215606
  20. The risk of colorectal cancer in ulcerative colitis: a meta-analysis.
    Gut. 2001 Apr;48(4):526-35 PMID: 11247898
  21. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases.
    Gastroenterology. 2004 May;126(6):1634-48 PMID: 15168373
  22. The fate of low grade dysplasia in ulcerative colitis.
    Am J Gastroenterol. 2002 Apr;97(4):922-7 PMID: 12008669
  23. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis.
    Am J Gastroenterol. 1995 Dec;90(12):2106-14 PMID: 8540497
  24. Failure of colonoscopic surveillance in ulcerative colitis.
    Gut. 1993 Aug;34(8):1075-80 PMID: 8174957
  25. Assessing disease activity and disease activity indices for inflammatory bowel disease.
    Curr Gastroenterol Rep. 2002 Dec;4(6):490-6 PMID: 12441039
  26. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.
    Gut. 2000 Sep;47(3):404-9 PMID: 10940279
  27. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.
    Gastroenterology. 1999 Dec;117(6):1288-94; discussion 1488-91 PMID: 10579969
  28. Colorectal cancer prevention in ulcerative colitis: a case-control study.
    Aliment Pharmacol Ther. 2000 Feb;14(2):145-53 PMID: 10651654
Article Info
Journal
Gastroenterology
Abbr.
Gastroenterology
ISSN
0016-5085
Published
2007-10-00
Epub
2007-00-02
Pages
1099-105; quiz 1340-1
Language
English
Region
United States
NLM ID
0374630
PMCID
PMC2175077
Subset
IM
Grants
NIDDK NIH HHS · K08 DK069393 · United States
NIDDK NIH HHS · K08 DK069393-01A1 · United States
NIDDK NIH HHS · K-08-DK069393 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]